A new study released by Johnson & Johnson shows two doses of the company’s COVID vaccine is 94% effective against the virus, prompting many recipients of the medication to ask if they should receive a booster shot heading into the fall season.
Since the vaccines became available, the injection from Johnson & Johnson was widely touted as a “one shot” solution for many Americans.
“Our large real-world-evidence and Phase 3 studies confirm that the single-shot Johnson & Johnson vaccine provides strong and long-lasting protection against COVID-19-related hospitalizations,” Dr. Mathai Mammen, global head of Janssen Research & Development, said in a statement.
“Our single-shot vaccine generates strong immune responses and long-lasting immune memory. And, when a booster of the Johnson & Johnson COVID-19 vaccine is given, the strength of protection against COVID-19 further increases.”
Nearly 15 million Americans have been given one dose of the J&J Vaccine since it was approved for emergency use authorization by the FDA on Feb. 27th.
“A second study showed people given a booster shot six months or longer after their first dose had a 12-fold increase in antibodies — compared to a four-fold increase for people who got a second dose at two months. So protection should be stronger if people get boosters later, Dr. Dan Barouch, head of Beth Israel Deaconess’ Center for Virology and Vaccine Research, told CNN,” reports the Cable News Network.
“The Johnson & Johnson single-shot COVID-19 vaccine showed vaccine effectiveness against COVID-19-related hospitalizations at 86% for participants younger than 60 years, and 78% for those 60 years and older,” the company said.
